QuantideX® qPCR BCR-ABL minor Kit (RUO)
The QuantideX® qPCR BCR-ABL minor Kit (RUO) is a clinical research tool enabling ultra-sensitive and precise detection of BCR-ABL1 minor fusion transcripts (e1a2) from whole blood specimens. Building on the simple workflow and best-in-class sensitivity established with the FDA-cleared QuantideX® qPCR BCR-ABL IS Kit, the minor Kit allows labs and clinical researchers to examine the biology of disease for this very rare but distinct leukemic variant with unprecedented ease.
Features & Benefits
The QuantideX qPCR BCR-ABL minor Kit (RUO) delivers high performance through unmatched sensitivity and optimized laboratory efficiency.
Reduced ComplexityEase-of-data analysis and reporting:
- Leverages the QuantideX® qPCR BCR-ABL IS Kit workflow concept for streamlined implementation
- Included software provides automated calculation of BCR-ABL1/ABL1 % ratio and eliminates the need for manual calculation
Optimized WorkflowValuable operator hands-on time has been significantly reduced through:
- Multiplexed design amplifies and detects both fusion and control gene in the same reaction
- All-inclusive reagents sourced and quality controlled together from a single vendor
- Pre-mixed reagents allow fewer pipetting steps in mastermix preparation
Quality PerformanceDetecting BCR-ABL1 minor transcripts robustly and reliably with a highly sensitive assay:
- Ultra-sensitive Limit of Detection (LOD): Log reduction of 4.61 (0.0025% ratio)
- Increased analytical sensitivity without compromising analytical specificity: incorporates Limit of Blank (LOB) to prevent miscalling of non-leukemic low positives
- Armored RNA®-based standards provide true RNA quantification
Analytical Characteristics
- Reproducible: Proven sensitivity based on rigorous testing criterion (Table 1)
- Precise: Minimal variability across entire dynamic range of BCR-ABL1/ABL1 % ratios (Table 2)
- Streamlined: Multiplexed design yields workflow and cost efficiencies (Figure 1)
Proven Sensitivity Based on Rigorous Testing Criterion
Table 1: LOD as determined by CLSI EP17-A2 guidelines by testing human RNA and cell line dilutions spanning lots, batch runs, days, operators and instruments.
Minimal Variability across Entire Dynamic Range
Table 2: Assay precision determined by testing 4 different log reduction (LR) levels in human RNA, using 2 operators and 8 runs for a total of 192 data points.
Multiplexed Design Yields Workflow and Cost Efficiency
Figure 1: Comparison of a plate layout for 8 sample run on Asuragen plate (left) and an alternate non-multiplex assay (right): 19 reactions for Asuragen setup vs. 52 reactions on a non-multiplex assay setup
Ordering
| Product Name | Number of Reactions | Catalog Number |
|---|---|---|
| QuantideX® qPCR BCR-ABL minor Kit (RUO) | 60 | 49637 |
T 512.681.5200 or 877.777.1874 F 512.681.5202 E orders@asuragen.com
QuantideX® qPCR BCR-ABL minor Kit
The BCR-ABL1 minor breakpoint (e1a2) constitutes a rare but distinct leukemic variant and accurate detection and quantitation of these fusion transcripts are paramount to improving outcomes for all chronic myeloid leukemia (CML) patients. The QuantideX® qPCR BCR-ABL minor Kit, an in vitro diagnostic (IVD) assay, enables ultra-sensitive detection of BCR-ABL1 minor fusion transcripts from whole blood specimens.
Features & Benefits
The QuantideX qPCR BCR-ABL minor Kit marries improved efficiency with unprecedented sensitivity, empowering labs to assess the deepest molecular responses in patients harboring the minor breakpoint with the ease-of-use they’ve come to expect from Asuragen.
Reduced ComplexityEase-of-data analysis and reporting:
- Shares a common workflow with the QuantideX® qPCR BCR-ABL IS Kit to reduce training burden and streamline test implementation
- Included software provides automated calculation of BCR-ABL1/ABL1 % ratio and the ability to report BCR-ABL Major on both the International Scale (IS) and copy number*
Optimized WorkflowValuable operator hands-on time has been significantly reduced through:
- Multiplexed design amplifies and detects both fusion and control gene in the same reaction
- All necessary RT and qPCR reagents sourced and quality controlled together from a single vendor
- Pre-mixed reagents allow fewer pipetting steps in mastermix preparation
Quality PerformanceDetecting BCR-ABL1 minor transcripts robustly and reliably with a highly sensitive assay:
- Ultra-sensitive Limit of Detection (LOD): Log reduction of 4.61 (0.0025% ratio)
- Increased analytical sensitivity without compromising analytical specificity: incorporates Limit of Blank (LOB) to prevent miscalling of non-leukemic low positives
- Armored RNA®-based standards provide true RNA quantification
Analytical Characteristics
- Reproducible: Proven sensitivity based on rigorous testing criterion (Table 1)
- Precise: Minimal variability across entire dynamic range of BCR-ABL1/ABL1 % ratios (Table 2)
- Streamlined: Multiplexed design yields workflow and cost efficiencies (Figure 1)
Proven Sensitivity Based on Rigorous Testing CriterionTable 1: LOD as determined by CLSI EP17-A2 guidelines by testing human RNA and cell line dilutions spanning lots, batch runs, days, operators and instruments.
Minimal Variability across Entire Dynamic Range
Table 2: Assay precision determined by testing 4 different log reduction (LR) levels in human RNA, using 2 operators and 8 runs for a total of 192 data points.
Multiplexed Design Yields Workflow and Cost Efficiency
Figure 1: Comparison of a plate layout for 8 sample run on Asuragen plate (left) and an alternate non-multiplex assay (right): 19 reactions for Asuragen setup vs. 52 reactions on a non-multiplex assay setup
Ordering
| Product Name | Number of Reactions | Catalog Number |
|---|---|---|
| QuantideX® qPCR BCR-ABL minor Kit | 60 | 49640 |
T +1 512.681.5200 or +1 877.777.1874 F +1 512.681.5202 E orders@asuragen.com
